BioSpace News Archive

- Milestone represents the first patient dosed with an OTS AdenoVerse immunotherapy targeting infectious disease - - RRP is a rare, difficult-to-treat neoplastic disease caused by HPV 6 or HPV 11 and currently has no proven effective systemic therapy -

Reltio, an award-winning provider of the only cloud-native master data management SaaS platform used by companies worldwide to succeed in the digital economy, today announced the introduction of Reltio Enterprise 360 Site Intelligence, a new cloud service that enables Pharmaceutical Research & Development Teams and Contract Research Organizations

Optellum , a lung health company aiming to redefine early diagnosis and treatment of lung disease, today announced it received FDA 510(k) clearance for its Virtual Nodule Clinic.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery, is excited to announce today that they have appointed J. Melville (“Mel”) Engle as Chief Executive Officer of the company.

Therap Services, the leading software solution for HIPAA-compliant electronic documentation for Home and Community-based Services (HCBS) and Long-Term Services and Supports (LTSS) providers, has interfaced with HHA Exchange for service providers in New Jersey.

RiverVest Venture Partners, a leading venture capital firm, announced today the closing of its RiverVest Venture Fund V, L.P. (“Fund V”), with $275 million of capital commitments in an oversubscribed fundraise.

Biodesix, Inc. a leading data-driven diagnostic solutions company with a focus in lung disease, announced that it has closed on a new $30 million term loan which matures on March 1, 2026.

Provectus Algae (Provectus), an Australian biotechnology company specialising in the optimisation of algae to produce high-value compounds for use in a wide array of industries and applications, today appointed Tim Lu, M.D., Ph.D., to its board of directors.

Novanta Inc., a trusted technology partner to medical and advanced technology equipment manufacturers, announced that its Board of Directors has appointed Matthijs Glastra, currently Chief Executive Office, to the additional role of Chairman of the Board, effective after the Company’s Annual Meeting of Shareholders on May 13, 2021.

Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today reported financial results for the fourth quarter and full year ended December 31, 2020.